Table 2.
Treatments trialed for metastatic meningiomas
| Novel therapy trialed | Number of times trialed |
|---|---|
| Tyrosine kinase inhibitors | 6 |
| Sunitinib | 3 |
| Valatinib | 2 |
| Apatinib (targets VEGFR2) | 1 |
| Synthetic somatostatin | 8 |
| Octreotide | 8 |
| Immunotherapy | 6 |
| Bevacizumab (anti-angiogenic) | 3 |
| Nivolumab (anti-PD-1) | 2 |
| Pembrolizumab (anti-PD-1) | 1 |
| Classical chemotherapy | 34 |
| Hydroxyurea | 14 |
| Temozolomide | 5a |
| Carboplatin | 3b |
| Doxorubicin | 3c |
| Paclitaxel | 2d |
| Vincristine-cyclophosphamide-doxorubicin | 2 |
| Ifosfamide | 2e |
| Etoposide | 2 |
| Cisplatin | 1f |
| Others | 2 |
| Thalidomide | 1 |
| Interferon therapy | 1 |
| Novel radiotherapeutic approaches | 3 |
| Peptide receptor radionucleotide therapy | 2 |
| Boron neutron capture therapy (BNCT) | 1 |
A summary of novel and innovative pharmacological therapies as well as novel radiotherapeutic approaches alongside more traditional chemotherapies. All patients received surgery and standard radiotherapy
aTreated once with hydroxyurea/temozolomide; btreated once with paclitaxel and once with etoposide; c treated once with ifosfamide; dtreated once with paclitaxel; etreated once with doxorubicin; f treated once with carboplatin and once with cisplatin